Novel non-TCR chromosome translocations t(3;11)(q25;p13) and t(X;11)(q25;p13) activating LMO2 by juxtaposition with MBNL1 and STAG2
In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) cytogenetic alterations juxtapose the LIM-domain-only-2 gene (LMO2) with T-cell receptor loci, chiefly TR@A/D via t(11;14)(p13;q11.2) and TR@B via t(7;11)(q35;p13). Recent studies 1,2 identifed a second alteration, a del(11)(p13) which removes a negative regulatory element (NRE) upstream of LMO2 (Figure 1 ). The significance of 5 0 -LMO2 is heightened by a retroviral insertion hotspot revealed thereat during gene therapy trials, abandoned when LMO2-positive T-lymphoproliferative disease emerged. LMO2 is aberrantly expressed in 9% pediatric T-ALL cases, 1 though higher figures have been reported. To seek factors underlying LMO2 dysregulation, we investigated a panel of T-ALL cell lines by integrative genomic and transcriptional analyses.
The 26 T-ALL cell lines analyzed in this study (http:// www.dsmz.de) are listed in Supplementary Table 1 . LMO2 rearrangements were identified in 5/26 (19.2%) cell lines. These comprised t(11;14)(p13;q11.2) in TALL-104, where the partner gene is TR@D confirming an earlier report, 2 and an additional four cell lines which tested positive for non-TCR alterations, namely: del(11)(p13p13) in P12/ICHIKAWA, t(3;11)(q25;p13) in MOLT-16 and t(X;11)(q25;p13) in MOLT-14 and PER-117. Both t(3;11) and t(X;11) are described in this study for the first time and represent a new class of rearrangement with distal 5 0 -LMO2 breakpoints.
Del(11)(p13p13) in P12/ICHIKAWA cells spans B2.5 Mbp hosting some 14 annotated genes (Figures 1 and 2a) . Concomitant NRE deletion was confirmed by fluorescence in situ hybridization (FISH) (Figure 2a) . No other T-ALL cell line in this study carried this deletion (not shown). In G-banded metaphases del(11) is undetectable in P12/ICHIKAWA cells (Figure 2a inset) .
FISH revealed an altogether different kind of LMO2 rearrangement in MOLT-16, t(3;11)(q25;p13) which cryptically exchanges similar sized and banded regions (Figure 2b ). The 11p13 breakpoint lies B155 Kbp upstream of LMO2. FISH placed the 3q25 breakpoint near the promoter region of the muscleblind-like protein 1 (MBNL1) gene ( Figure 1 ) ubiquitously expressed in hematopoietic cells and hitherto known for the toxic sequestration of its protein to RNA repeats in myotonic dystrophy.
A second non-TCR LMO2 rearrangement, t(X;11)(q25;p13), was found in both MOLT-14 and PER-117 cells (Figures 2c  and d ). Unadorned t(X;11) as present in MOLT-14 cells is cryptic (Figure 2c inset), while in PER-117 cells formation of t(X;1;11)(q25;p13;p13) renders it visible (Figure 2d lower), Figure 1 Loci and breakpoints. Boxes indicate BAC (clear) and fosmid (black) clones for LMO2, MBNL1 and STAG2 analyzed by fluorescence in situ hybridization. Arrows show breakpoints reported in this study together with published patient breakpoints (arrowheads). Note how published breakpoints hug the LMO2 promoter, while t(3;11) and t(X;11) breakpoints lie 85-170 Kbp upstream implying distinct modus operandi. cen, centromeric; DP/PP, distal/proximal promoter; NRE, negative regulatory element; tel, telomeric.
enabling detection in the donor patient. 3 Mapping with tilepath clones placed the 11p13 breakpoint of MOLT-14 B85 Kbp upstream of LMO2, while that of PER-117 lay B170 Kbp upstream ( Figure 1 ). Fluorescence in situ hybridization placed the Xq25 breakpoint in MOLT-14 just inside the stromal antigen 2 (STAG2) gene (Figure 2c ). In PER-117 cells the Xq25 breakpoint also lay within STAG2 (Figure 2d ), B40 Kbp downstream of MOLT-14 near an alternative promoter ( Figure 1 ). Hence, t(X;11) in both MOLT-14 and PER-117 juxtaposes the far upstream region of LMO2 (retaining NRE) with intron 1 of STAG2, ubiquitously expressed in hematopoietic cells. Crucially, t(3;11)/(X;11) breakpoints cluster far (85-170 Kbp) upstream of LMO2, distinct from canonical breakpoints which hug the distal promoter ( Figure 1 ) pointing to distinct modus operandi.
To investigate possible LMO2 fusion with MBNL1 or STAG2, 5 0 -random amplification of complementary DNA ends was performed using RNA from MOLT-14/16 and PER-117 (Supplementary Figure 1 ). No evidence of fusion was found, and sequencing confirmed wild-type LMO2 only. Similarly, reverse transcriptase-PCR using a variety of primers from LMO2 and either MBNL1 or STAG2 failed to amplify product (not shown). These findings show that t(X;11) and t(3;11) do not transcribe hybrid LMO2 RNA.
MBNL1 exchanges promoters with BCL6 in B-cell lymphoma, 4 underlining the potency of this region in an hematopoietic context. Although loss of STAG2, part of the complex controlling sister chromatid cohesion during the cell cycle, promotes chromosome instability, 5 neither MOLT-14 nor PER-117 display conspicuously aberrant karyotypes. Although this is the first report indicting STAG2 in a leukemic translocation, the cis-regulatory potential of its 5 0 -region is known. 6 Real-time quantitative-PCR analysis of 26 T-ALL cell lines (Figure 3a) showed LMO2 upregulation correlated with genomic rearrangement, which occurred in 5 of the top 10 (50%) expressers, but not in the remaining 16 (t-test: Po0.001). Our data also hint that the degree of LMO2 upregulation may be rearrangement-class dependent, TCR-/NRE-deletion cells trumping t(3;11)/t(X;11). Real-time quantitative-PCR showed significant (t-test: Po0.05) STAG2 silencing in both t(X;11) cell lines in contrast to uniformly high expression in 12 T-ALL controls (Figure 3b ). Mechanisms underlying dysregulation in remaining LMO2-cell lines remain unknown. Allele-specific PCR shows that LMO2 expression in T-ALL is normally monoallelic, underlining cis-(de)regulation. 7 Thus, cytogenetically silent LMO2 expression may indicate hidden regulatory DNA or epigenetic alterations.
Reverse transcriptase-PCR analysis of MBNL1 in MOLT-16 with t(3;11) and 11 cytogenetically silent T-ALL cell lines revealed ubiquitous expression (Figure 3c ). Microarray profiling of MBNL1 which yields multiple transcripts confirmed that, while 4/11 transcripts are spared by t(3;11), the remaining seven are silenced. Collectively, these findings support sacrificial activation of LMO2 by MBNL1 or STAG2 via t(3;11) and t(X;11), respectively. The remoteness of the upstream LMO2 breakpoints in MOLT-14/16 and PER-117, together with their juxtaposition to regulatory regions derived from MBNL1 or STAG2, resembles BCL11B translocations which also sacrifice remote enhancers to activate TLX3/NKX2-5 in T-ALL, irrespective of target gene orientation. 8 It is likely that other LMO2-activating regions await discovery in 'orphan' non-TCR, LMO2-positive T-ALLs.
Although all three t(X;11)/(3;11) cell lines represent relapsed pediatric T-ALL patients, their maturation stages are heterogeneous: MOLT-14 is TCRgd þ and MOLT-16 is TCRab þ (both T-IV), while PER-117 (T-II) is pre-T (Supplementary Table 2 ). The expression profiles of PER-117, MOLT-14 and MOLT-16 are distinct, the latter pair more closely resembling T-ALL cell lines in general (Supplementary Table 3 ). LMO2 expression is restricted to early thymocytes, where sustained activation may induce reprogramming 9 and prolong survival. 10 Among cell lines, there was no correlation between LMO2 expression and maturation-levels. Increased thymocyte survival may permit acquisition of oncogenic mutations. 10 Accordingly, all three cell lines display various additional changes: mutations of FBXW7, CDKN2A, p14, MSH2, NOTCH1, NRAS, TP53, in MOLT-14 and CDKN2A, p14 and TP53 in MOLT-16 (http://www.sanger. ac.uk/). MOLT-14 carries MYC-TCRD and SIL-TAL1, and PER-117, 14q32 rearrangements, 3 perhaps explaining BCL11B silencing therein (Supplementary Table 3) .
How might non-TCR LMO2-translocations have escaped notice until now? First, most LMO2 breakpoints have been detected by Southern blotting or by ligation-mediated PCR, both favoring local breakpoints. Second, t(X;11)/(3;11) cell lines are from relapse cases and may be rarer at diagnosis. Third, both t(X;11) and t(3;11) are occult. T-ALL cases with Xq25/3q25 involvement are shown in Supplementary Tables 4A/B including two with t(X;11). Collectively, our data support screening LMO2-positive T-ALL for conspicuous STAG2 or MBNL1 silencing, notably in cases lacking TCR involvement.
In summary, we identified a novel class of T-ALL rearrangement, which juxtaposes the far upstream region of LMO2 with regulatory introns of MBNL1 or STAG2, with moderate LMO2 upregulation. Their remoteness from LMO2 distinguishes these figure) . Collectively, these results are consistent with LMO2 upregulation via capture of MBNL1 or STAG2 regulatory elements effected by t(3;11) or t(X;11), respectively. Data are means of three or more biological replicates. from existing rearrangements. We also identified three cell line models for investigating the pathology of, and therapeutic targets in, this apparently novel LMO2 subtype.
